Takeda Pharmaceutical Company Limited
TAK
$18.37
$0.090.49%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 775.80M | 259.30M | 958.61M | 709.46M | 1.37B |
| Total Depreciation and Amortization | 4.73B | 4.72B | 4.76B | 4.73B | 4.79B |
| Total Amortization of Deferred Charges | 265.19M | 265.19M | 265.19M | 265.19M | 219.53M |
| Total Other Non-Cash Items | 2.49B | 2.27B | 1.48B | 1.64B | 1.01B |
| Change in Net Operating Assets | -320.93M | 516.29M | -108.88M | -390.04M | -8.90M |
| Cash from Operations | 7.94B | 8.03B | 7.36B | 6.96B | 7.38B |
| Capital Expenditure | -1.19B | -1.22B | -1.28B | -1.32B | -1.30B |
| Sale of Property, Plant, and Equipment | 44.52M | 44.47M | 44.67M | 515.30K | 318.80K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 297.70M | 285.42M | 319.28M | 135.34M | 195.38M |
| Other Investing Activities | -1.32B | -553.52M | -705.69M | -1.22B | -1.58B |
| Cash from Investing | -2.18B | -1.44B | -1.62B | -2.40B | -2.68B |
| Total Debt Issued | 553.55B | 593.55B | 727.87B | 1.05T | 1.02T |
| Total Debt Repaid | -730.36B | -1.23T | -1.47T | -1.37T | -1.15T |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -101.58B | -101.58B | -101.58B | -51.86B | -1.88B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.10B | -2.08B | -2.09B | -1.97B | -1.96B |
| Other Financing Activities | -129.88B | -135.99B | -127.54B | -82.75B | -79.00B |
| Cash from Financing | -4.80B | -7.85B | -8.51B | -4.99B | -3.40B |
| Foreign Exchange rate Adjustments | 155.74M | 160.13M | -211.61M | -84.27M | 50.52M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.12B | -1.10B | -2.99B | -517.05M | 1.34B |